Yestar Health posts interim loss as revenue dips amid China procurement policy
Stock News
Aug 28
Yestar Health (02393) has released its interim results for the six months ended June 30, 2026, revealing a net loss attributable to shareholders of RMB 3.168 million, a sharp reversal from the profit of RMB 5.761 million recorded during the same period last year.
The company generated revenue of RMB 662 million for the period, marking a 17.57% decline year-on-year. The loss per share stood at RMB 0.14 cent.
According to the announcement, the drop in revenue is primarily attributed to the medical segment—the group's main income source—which has been adversely impacted by China's centralized procurement policies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.